PMID- 23978988
OWN - NLM
STAT- MEDLINE
DCOM- 20140428
LR  - 20221207
IS  - 1432-0843 (Electronic)
IS  - 0344-5704 (Linking)
VI  - 72
IP  - 4
DP  - 2013 Oct
TI  - Efficacy and safety of everolimus in Korean patients with metastatic renal cell 
      carcinoma.
PG  - 853-60
LID - 10.1007/s00280-013-2266-y [doi]
AB  - PURPOSE: Few studies have investigated the effects of everolimus therapy in Asian 
      populations. This study evaluates the safety and efficacy of everolimus in Korean 
      patients with metastatic renal cell carcinoma (mRCC). METHODS: We retrospectively 
      reviewed records of Korean patients with mRCC (n = 22) who received everolimus 
      between January 2009 and July 2010 and evaluated them for efficacy and safety. 
      RESULTS: One patient achieved a partial response, and 16 patients had stable 
      disease, corresponding to an overall response rate of 4.5 % and a disease control 
      rate of 77.3 %. Median progression-free survival was 5.4 months (95 % CI 
      0.9-9.8). Median overall survival was not reached. Univariate analysis showed 
      that Memorial Sloan-Kettering Cancer Center risk (P = .004), thrombocytopenia 
      (P = .018), hyperglycemia (P = .007) and hypertriglyceridemia (P = .041) were 
      associated with disease progression. The most common adverse events (AEs) were 
      hypertriglyceridemia and anemia, similar to Western patients. Creatinine and 
      aspartate aminotransferase levels were higher than those reported for Western 
      patients. The most common grade >/=3 AEs in this study were hypertriglyceridemia 
      and anemia, compared with lymphopenia (14 %) in Western patients. CONCLUSIONS: 
      Safety of everolimus in Korean mRCC patients differed from that reported in 
      Western patients. Therefore, liver function enzymes, hemoglobin levels, lipid 
      profile and chest CT scans should be monitored more closely in Asian mRCC 
      patients receiving everolimus.
FAU - Kim, Ki Hyang
AU  - Kim KH
AD  - Division of Medical Oncology, Department of Internal Medicine, Busan Paik 
      Hospital, Inje University College of Medicine, Busan, South Korea.
FAU - Yoon, Sang Hyun
AU  - Yoon SH
FAU - Lee, Hae-Jung
AU  - Lee HJ
FAU - Kim, Hyo Song
AU  - Kim HS
FAU - Shin, Sang Joon
AU  - Shin SJ
FAU - Ahn, Joong Bae
AU  - Ahn JB
FAU - Rha, Sun Young
AU  - Rha SY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130827
PL  - Germany
TA  - Cancer Chemother Pharmacol
JT  - Cancer chemotherapy and pharmacology
JID - 7806519
RN  - 0 (Antineoplastic Agents)
RN  - 9HW64Q8G6G (Everolimus)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Aged
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Asian People
MH  - Carcinoma, Renal Cell/*drug therapy/pathology
MH  - Disease-Free Survival
MH  - Drug Monitoring/methods
MH  - Everolimus
MH  - Female
MH  - Humans
MH  - Kidney Neoplasms/*drug therapy/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Republic of Korea
MH  - Retrospective Studies
MH  - Sirolimus/adverse effects/*analogs & derivatives/therapeutic use
MH  - Survival Rate
MH  - Treatment Outcome
EDAT- 2013/08/28 06:00
MHDA- 2014/04/29 06:00
CRDT- 2013/08/28 06:00
PHST- 2013/07/02 00:00 [received]
PHST- 2013/08/07 00:00 [accepted]
PHST- 2013/08/28 06:00 [entrez]
PHST- 2013/08/28 06:00 [pubmed]
PHST- 2014/04/29 06:00 [medline]
AID - 10.1007/s00280-013-2266-y [doi]
PST - ppublish
SO  - Cancer Chemother Pharmacol. 2013 Oct;72(4):853-60. doi: 
      10.1007/s00280-013-2266-y. Epub 2013 Aug 27.